Patients with certain inflammatory diseases may benefit from receptor agonists
Investigators examined whether glucagon-like peptide-1 receptor agonists may reduce the risk of mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and Type 2 diabetes.
In a study published in PLOS ONE, the investigators analyzed the outcomes of 10,855 patients with immune-mediated inflammatory diseases — including psoriatic disease, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and systematic autoimmune rheumatic diseases — who received either GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors between 2010 and 2021.
Compared with the patients who received DPP-4 inhibitors, the patients who received GLP-1 receptor agonists had a significantly lower likelihood of experiencing all-cause mortality or major adverse cardiovascular events.
The investigators suggested that GLP-1 receptor agonists may have cardioprotective effects that could be consistent across patients with and without immune-mediated inflammatory diseases. However, further studies may be needed to confirm the findings prior to recommending changes to clinical practice.
Read more: PLOS ONE
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.